CR20140333A - Composiciones que contienen inhibidores de quinasas - Google Patents

Composiciones que contienen inhibidores de quinasas

Info

Publication number
CR20140333A
CR20140333A CR20140333A CR20140333A CR20140333A CR 20140333 A CR20140333 A CR 20140333A CR 20140333 A CR20140333 A CR 20140333A CR 20140333 A CR20140333 A CR 20140333A CR 20140333 A CR20140333 A CR 20140333A
Authority
CR
Costa Rica
Prior art keywords
compositions containing
kinase inhibitors
compositions
containing kinase
pharmaceutically acceptable
Prior art date
Application number
CR20140333A
Other languages
English (en)
Inventor
Yi Shi
John M Lipari
Brian E Padden
Lloyd E Dias
Julie K Spence
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47559656&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20140333(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of CR20140333A publication Critical patent/CR20140333A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Composiciones que comprenden un compuesto que puede inhibir las quinasas, tal como la N-(4-{4-amino-7-[1-(2-hidroxietil)-1H-pirazol-4-il]tieno[3,2-c]piridin-3-il}fenil)-N'-(3-fluorofenil)urea, en una mezcla que comprende (a) un vehículo polimérico soluble en agua farmacéuticamente aceptable y (b) un agente tensioactivo farmacéuticamente aceptable. Estas composiciones son apropiadas para diluirlas con soluciones IV y administrárselas a aquellos sujetos que necesitan ser sometidos a un tratamiento contra un cáncer.
CR20140333A 2011-12-14 2014-07-10 Composiciones que contienen inhibidores de quinasas CR20140333A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161570679P 2011-12-14 2011-12-14

Publications (1)

Publication Number Publication Date
CR20140333A true CR20140333A (es) 2014-09-29

Family

ID=47559656

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140333A CR20140333A (es) 2011-12-14 2014-07-10 Composiciones que contienen inhibidores de quinasas

Country Status (25)

Country Link
US (1) US20150126545A1 (es)
EP (1) EP2790726A1 (es)
JP (1) JP2015500343A (es)
KR (1) KR20150000869A (es)
CN (1) CN103987406A (es)
AR (1) AR089248A1 (es)
AU (1) AU2012352112A1 (es)
BR (1) BR112014014342A2 (es)
CA (1) CA2857337A1 (es)
CL (1) CL2014001548A1 (es)
CO (1) CO7010829A2 (es)
CR (1) CR20140333A (es)
DO (1) DOP2014000128A (es)
EC (1) ECSP14008671A (es)
HK (1) HK1203368A1 (es)
IL (1) IL232725A0 (es)
MX (1) MX2014007158A (es)
PE (1) PE20142103A1 (es)
PH (1) PH12014501333A1 (es)
RU (1) RU2014128601A (es)
SG (1) SG11201402776WA (es)
TW (1) TW201330850A (es)
UY (1) UY34518A (es)
WO (1) WO2013090666A1 (es)
ZA (1) ZA201404134B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017014084A (es) * 2015-05-05 2018-06-20 Psivida Inc Formulaciones de deposito inyectables.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7202363B2 (en) 2003-07-24 2007-04-10 Abbott Laboratories Thienopyridine and furopyridine kinase inhibitors
TWI441827B (zh) 2008-12-05 2014-06-21 Abbvie Bahamas Ltd 具改良ｃｙｐ安全性之激酶抑制劑
WO2010101971A1 (en) * 2009-03-03 2010-09-10 Alcon Research, Ltd. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye
US8557995B2 (en) * 2010-06-09 2013-10-15 Abbvie Inc. Solid dispersions containing kinase inhibitors

Also Published As

Publication number Publication date
AU2012352112A1 (en) 2014-06-12
PH12014501333B1 (en) 2014-09-15
PE20142103A1 (es) 2015-01-11
RU2014128601A (ru) 2016-02-10
MX2014007158A (es) 2014-08-29
HK1203368A1 (en) 2015-10-30
KR20150000869A (ko) 2015-01-05
CO7010829A2 (es) 2014-07-31
EP2790726A1 (en) 2014-10-22
AR089248A1 (es) 2014-08-06
PH12014501333A1 (en) 2014-09-15
TW201330850A (zh) 2013-08-01
DOP2014000128A (es) 2014-08-15
CN103987406A (zh) 2014-08-13
IL232725A0 (en) 2014-07-31
UY34518A (es) 2013-07-31
BR112014014342A2 (pt) 2017-06-13
WO2013090666A1 (en) 2013-06-20
ECSP14008671A (es) 2015-11-30
JP2015500343A (ja) 2015-01-05
CA2857337A1 (en) 2013-06-20
CL2014001548A1 (es) 2014-10-10
ZA201404134B (en) 2015-02-25
SG11201402776WA (en) 2014-06-27
US20150126545A1 (en) 2015-05-07

Similar Documents

Publication Publication Date Title
MX2012014387A (es) Dispersiones solidas que contienen inhibidores de cinasa.
WO2015095819A3 (en) Cancer treatment using combinations of erk and raf inhibitors
BR112012023021A2 (pt) compostos de indazol e seus usos
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
WO2009017838A3 (en) Combinations of jak-2 inhibitors and other agents
MX2013004491A (es) Boronatos como inhibidores de arginasa.
MY171553A (en) Pyrrolotriazinone derivatives as pi3k inhibitors
BR112014009365A2 (pt) método para inibição da atividade de deubiquitinação
MX2014008284A (es) Formulacion de liberacion retardada para reducir la frecuencia de orinar y metodos de uso de esta.
WO2012145575A3 (en) Therapy for leukemia
MX2014003025A (es) Compuestos de triazolopiridina como inhibidores de fosfodiesterasa 10a.
PH12014502294A1 (en) Triazolo compounds as pde10 inhibitors
MX2014008283A (es) Formulacion de liberacion prolongada para reducir la frecuencia de orinar y metodos de uso de esta.
AR043822A1 (es) Formas de dosificacion y procedimientos de tratamiento que usan inhibidores del vegfr
NZ630471A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
MX2016003522A (es) Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa.
MX2012014386A (es) Formas cristalinas de inhibidores de cinasa.
NZ705389A (en) Methods of treating hair related conditions
MX359713B (es) Composiciones mejoradas para la cicatrizacion de heridas que comprenden microesferas.
CR20140333A (es) Composiciones que contienen inhibidores de quinasas
MX342511B (es) Metodos y composiciones para tratar la enfermedad de raynaud.
BR112015005392A2 (pt) formulação de comprimido de um inibidor de fosfatidilinositol 3-cinase
DOP2013000266A (es) Compuestos para el tratamiento y prevención de las adherencias, composiciones farmacéuticas de los compuestos relacionados y métodos para el tratamiento y la prevención de las adherencias
MX2012014385A (es) Formas cristalinas de inhibidores de cinasa.
NZ604649A (en) Crystalline forms of kinase inhibitors